A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania

• ClinicalTrials.gov Identifier: NCT04788862
• Recruitment Status: Not yet recruiting
• First Posted: March 9, 2021
• Last Update Posted: September 16, 2021
• Sponsor: University of Oxford
• Collaborator: Ifakara Health Institute
• Information provided by (Responsible Party): University of Oxford

Study Description

Brief Summary:

This will be a single-centre, open label trial to determine the safety and feasibility of CHMI model using Plasmodium falciparum-infected cryopreserved erythrocytes administered to healthy Tanzanian adults with varying prior exposure to P. falciparum.

Condition or disease	Intervention/treatment	Phase
Malaria; Plasmodium Falciparum	Biological: P. falciparum infected erythrocytes	Not Applicable

Detailed Description:

This study will be a single-centre controlled human malaria infection study using adults with varying degrees of prior exposure to P. falciparum. The study will take place at Bagamoyo Clinical Trail Facility of the Ifakara Health Institute, located in Bagamoyo town (about 60 km north of Dar es Salaam).

Twelve healthy male adults aged 18 to 35 years will be recruited into two cohorts of high and low previous exposure consisting of 6 volunteers each as determined by anti-schizont antibody levels. Up to 5 back-up volunteers will be also be recruited and may take the place of another volunteer should they withdraw or become ineligible prior to challenge.

Participants will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes of the chloroquine-susceptible 3D7 strain. Participants will then be closely monitored in a clinical trial facility for a maximum of 31 (28 days plus 3 days of treatment with anti-malarial drugs) days while undergoing frequent clinical and laboratory assessment. Volunteers who do not reach malaria treatment criteria as per protocol at day 28 (C+28) will be treated presumptively with antimalarial medications (ALU + a single low dose primaquine) under direct observation and will be discharged upon completion of treatment and on discretion of the study clinician.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Open Label Trial to Establish a Blood-stage Controlled Human Malaria Infection Model and Determine Its Safety in Healthy Tanzanian Adults With Varying Prior Exposure to P. Falciparum
• Estimated Study Start Date: January 15, 2022
• Estimated Primary Completion Date: June 30, 2022
• Estimated Study Completion Date: June 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group 1: High prior P. falciparum exposure; 6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.	Biological: P. falciparum infected erythrocytes; Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
Experimental: Group 2: Low prior P. falciparum exposure; 6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.	Biological: P. falciparum infected erythrocytes; Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.

Outcome Measures

Primary Outcome Measures :

1. Occurrence of adverse events to assess the safety of controlled blood-stage P. falciparum [ Time Frame: 98 days ]
   Frequency and severity of clinical and laboratory Adverse Events and Serious Adverse Events
2. Development of parasitaemia to assess the feasibility of controlled blood-stage P. falciparum [ Time Frame: 28 days ]
   Proportion of participants who develop detectable parasitaemia post-CHMI as measured by qPCR
3. Development of parasitaemia to assess the feasibility of controlled blood-stage P. falciparum [ Time Frame: 28 days ]
   Proportion of participants who develop sustained parasitaemia detectable by qPCR that is then spontaneously cleared
4. Parasite multiplication rates to assess the feasibility of controlled blood-stage P. falciparum [ Time Frame: 28 days ]
   Determine parasite multiplication rates as calculated by fitting established models to quantitative PCR data, as routinely done in the published studies (Payne et al., JID 2016; Minassian et al., submitted)

Secondary Outcome Measures :

1. Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis [ Time Frame: 98 days ]
   P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses. Determined by ELISA (concentration of antibodies)
2. Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis [ Time Frame: 98 days ]
   P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses. Determined by ELISpot (spots per 10^x PBMCs)
3. Cellular and Humoral Immune responses level at C-1, C+7, C+14, C+21, C+28, C+56, C+98 and diagnosis [ Time Frame: 98 days ]
   P. falciparum specific immunogenicity following P. falciparum blood-stage infection, as assessed by antibody, B cell and T cell responses. Determined by flow cytometry (% of immune cell sub-population)
4. To determine the effect of pre-exposure to malaria on parasite multiplication rates following controlled blood-stage P. falciparum infection. [ Time Frame: 28 days ]
   Comparison of PMRs between participants with low and high prior exposure to P. falciparum.
5. To determine if malaria infection following inoculation of P. falciparum is caused by the inoculum parasite strain and not wild-type strains [ Time Frame: 28 days ]
   Determine whole genome sequences (via whole genome analysis) following controlled blood-stage P. falciparum infection to confirm malaria infection is with inoculum strain and not wild-type parasite

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 35 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Volunteer being adult male aged ≥ 18 and ≤ 35 years, and in good health.
2. Volunteer a resident in Bagamoyo town or rural areas of Bagamoyo district for the past 6 months
3. Able and willing to complete the informed consent process conducted in English
4. Volunteer has adequate understanding of the procedures of the study and is able and willing (in the investigator's opinion) to comply with all study requirements.
5. Volunteer is willing to complete an informed consent questionnaire and is able to answer all questions correctly in a maximum of two attempts.
6. Volunteer is able to communicate well with the investigator and is willing to be monitored in an inpatient setting for 28 days after challenge with infected erythrocytes.
7. The volunteer agrees to refrain from blood donation throughout the study period.
8. Volunteer agrees to refrain from intensive physical exercise (disproportionate to the volunteer's usual daily activity or exercise routine) during the malaria challenge period.
9. Volunteer has signed written informed consent to participate in the trial.

Exclusion Criteria:

1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, gastrointestinal, renal, hepatic, neurological, dermatological (e.g. psoriasis, contact dermatitis etc.), allergy, endocrine, malignant, haematological, infectious, immunodeficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results.
2. A heightened risk of cardiovascular disease, as determined by: an estimated ten-year risk of fatal cardiovascular disease of ≥5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia, prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family history of cardiac events in 1st or 2nd degree relatives <50 years old.
3. A medical history of functional asplenia.
4. History of epilepsy in the period of five years prior to study onset, even if no longer on medication.
5. Confirmed parasite positive by PCR a day before challenge i.e., at C-1.
6. Screening tests positive for Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)
7. Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral antihistamines exempted) or expected use of such during the study period
8. Any recent or current systemic therapy with an antibiotic or drug with potential antimalarial activity (chloroquine, doxycycline, tetracycline, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, erythromycin, hydroxychloroquine, etc.) (allowable time frame for use at the Investigator's discretion).
9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
10. Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
11. History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
12. Previous participation in any malaria investigational product study (allowable time frame for use at the Investigator's discretion)
13. Known hypersensitivity to or contra-indications (including co-medication) for use of chloroquine, artemether-lumefantrine, Primaquine or history of severe (allergic) reactions to blood transfusion.
14. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period.
15. Being an employee or relative of an employee of Ifakara Health Institute.
16. Any other condition or situation that would, in the opinion of the investigator, place the volunteer at an unacceptable risk of injury or render the volunteer unable to meet the requirements of the protocol.

Exclusion criteria on day of challenge:

1. Acute disease, defined as moderate or severe illness with or without fever
2. Current COVID-19 infection, defined as ongoing symptoms with positive COVID-19 PCR swab test taken during current illness or positive COVID-19 PCR swab test within preceding 14 days without symptoms.
3. History of close contact with COVID-19 confirmed case within preceding 14 days

Contacts and Locations

Contacts

Contact: Angela Minassian, Dr; +44865611425; angela.minassian@ndm.ox.ac.uk

Contact: Ally Olotu, Dr; aolotu@ihi.or.tz

Locations

Tanzania

Ifakara Health Institute

Bagamoyo, Tanzania

Contact: Ally Olotu, Dr +255718927104 aolotu@ihi.or.tz

Contact: Florence Milando, Dr +255712935292

Sponsors and Collaborators

University of Oxford

Ifakara Health Institute

Investigators

• Principal Investigator: Angela Minassian, Dr; University of Oxford

More Information

• Responsible Party: University of Oxford
• ClinicalTrials.gov Identifier: NCT04788862
• Other Study ID Numbers: VAC083
• First Posted: March 9, 2021
• Last Update Posted: September 16, 2021
• Last Verified: September 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Oxford:

Malaria Challenge; Controlled Human Malaria Challenge

Additional relevant MeSH terms:

Malaria; Infections; Protozoan Infections; Parasitic Diseases; Vector Borne Diseases